Amplia Therapeutics ACCENT Trial Data Accepted at ASCO Annual Meeting

Release Highlights:

• Amplia is pleased to announce that data from the ACCENT trial of narmafotinib in advanced pancreatic cancer patients has been accepted and published in the online abstracts for the annual meeting of the American Society of Clinical Oncology (ASCO).
• The ASCO meeting, to be held in Chicago from May 31 – June 4 2024, is the largest and most significant oncology conference held annually and is attended by practicing oncologists, related healthcare providers, pharma and biotech representatives, academics, and patient advocacy groups
• The acceptance and publication of ACCENT trial data improves visibility of the program to potential commercial partners, as well as to oncologists working in pancreatic cancer.